


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,
Washington, D.C. 20231 on May 20, 1999

David Saliwanchik

David R. Saliwanchik, Patent Attorney



INFORMATION DISCLOSURE
STATEMENT

Patent Application
Docket No. SPO-103
Serial No. 09/142,524
Art Unit: 1646

RECEIVED

AUG 28 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Art Unit : 1646
Applicant(s) : Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama, Kohsuke Kino
Serial No. : 09/142,524
Filed : September 9, 1998
For : Peptide-based Immunotherapeutic Agent For Treating Allergic Diseases

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

JUN 1 1999

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

TECH CENTER 1600/2900

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

David Saliwanchik

David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address : 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

DRS/la

Enclosures: as stated above